<DOC>
	<DOC>NCT01285505</DOC>
	<brief_summary>This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing sublingual formulation.</brief_summary>
	<brief_title>Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation</brief_title>
	<detailed_description />
	<mesh_term>Alprazolam</mesh_term>
	<criteria>healthy male or female subjects BMI 18 to 26.9 must give informed consent clinically significant disease narrow angle glaucoma positive drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>alprazolam</keyword>
	<keyword>sublingual</keyword>
	<keyword>bioequivalence</keyword>
</DOC>